SAN FRANCISCO, CA, Expedition Therapeutics, a biotech company, announced the closing of an oversubscribed and upsized $165 million Series A financing.
Expedition Therapeutics, a biotech company developing therapies for novel inflammatory and respiratory diseases, announced the closing of an oversubscribed and upsized $165 million Series A financing. The round was co-led by Sofinnova Investments and Novo Holdings, with additional investment from Forbion, Dawn Biopharma (a platform controlled by KKR), Adage, Balyasny, Logos Capital, Sanofi Ventures, and existing investors BVF Partners and Venrock Healthcare Capital Partners.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.